Infectious Disease Advisor: Real-world data on BIC/FTC/TAF switch and long-acting ART in patients with viremia
- It Starts and Ends with Us: Community at the Centre of Clinical Studies
- Donate
- Get involved
- Subscribe
Infectious Disease Advisor: Real-world data on BIC/FTC/TAF switch and long-acting ART in patients with viremia
Back to the “HIV and Co-Infections News” list
- HIV Treatment
August 7, 2026
Tags:
- Long-Acting Antiretrovirals
Infectious Disease Advisor news stories
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Real-world data support BIC/FTC/TAF switch in adults with HIV
Switching to bictegravir plus emtricitabine and tenofovir alafenamide (BIC/FTC/TAF) represents a safe and effective regimen-optimization strategy among individuals with HIV who are virologically suppressed on antiretroviral therapy, according to study findings published in Infectious Diseases and Therapy
Long-acting ART achieves HIV virologic suppression in patients with viremia
Real-world data support long-acting antiretroviral therapy (ART) for people with HIV, including among those who are viremic at initiation, according to study findings published in Clinical Infectious Diseases
Related HIV and Co-Infections News
See all related HIV and Co-Infections News
- August 7, 2026
Contagion Live: Redefining HIV management: Emerging antiretroviral drug classes and immunologic strategies shaping the future of HIV treatment, prevention
- August 6, 2026
[AIDS 2026] aidsmap: Returning to HIV care does not erase the effects of treatment interruption, studies show
- August 5, 2026
HIV i-Base: AIDS 2026: New HIV drugs in the ART pipeline
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
- Become a member
- Support us
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your inbox
This website uses cookies. Some cookies are necessary for the proper functioning of the website and can not be refused if you want to visit this website. Other cookies are used for social network sharing, video playback and analysis purposes. You can refuse them if you want. Read our cookie policy
